Elevance Health Earnings
Elevance Health, Inc. (NYSE: ELV), a leader in the healthcare industry, has revealed its financial performance for the fourth quarter and the entire fiscal year of 2024. The company's focus on innovation and strategic growth has led to impressive results, demonstrating robust financial health and operational success.
Financial Overview
| Metric | Q4 2024 | Q4 2023 | YoY Change | FY 2024 | FY 2023 | YoY Change |
|---|---|---|---|---|---|---|
| Operating Revenue | $45.0B | $42.5B | +6% | $175.2B | $170.2B | +3% |
| Diluted EPS | $1.81 | - | - | $25.68 | - | - |
| Adjusted Diluted EPS | $3.84 | - | - | $33.04 | - | - |
Elevance Health's revenue rose to $45.0 billion in Q4 2024, up 6% from Q4 2023. This growth was primarily fueled by strategic acquisitions and increased premium yields within the Health Benefits segment. For the full year 2024, the company reported revenue of $175.2 billion, marking a 3% increase from the previous year. These figures reflect the company's strategic emphasis on maintaining a diversified and robust portfolio that meets the evolving needs of the healthcare industry.
Elevance Health Results
In its latest results, Elevance Health has illustrated a significant increase in its earnings metrics, reinforcing its financial stability. The diluted earnings per share (EPS) was reported at $1.81 for Q4, contributing to a full-year EPS of $25.68. On an adjusted basis, the diluted EPS was $3.84 for the quarter, leading to a remarkable $33.04 for the entire fiscal year. These strong earnings figures demonstrate Elevance Health's ability to effectively manage its business operations and deliver value to its shareholders.
Revenue Breakdown
A closer look at Elevance Health's revenue segments provides insight into the company's performance:
| Segment | Q4 2024 Revenue | Q4 2023 Revenue | YoY Change | FY 2024 Revenue | FY 2023 Revenue | YoY Change |
|---|---|---|---|---|---|---|
| Health Benefits | $37.6B | $36.6B | +3% | $150.3B | $148.6B | +1% |
| Carelon | $14.7B | $12.4B | +19% | $53.9B | $48.0B | +12% |
The Health Benefits segment witnessed growth due to increased premium yields, reflecting strong demand and effective pricing strategies in the competitive healthcare sector. Meanwhile, the Carelon segment recorded a remarkable 19% revenue growth in Q4 2024, driven by the launch of new risk-based capabilities and strategic acquisitions. This substantial growth underscores the company's commitment to expanding its healthcare models and extending its market reach.
Key Developments
Elevance Health's key developments this quarter highlight its strategic initiatives and commitment to shareholder returns:
- Dividend Increase : A 5% increase in the quarterly dividend resulted in a dividend of $1.71 per share.
- Share Repurchase : The company repurchased 4.5 million shares, totaling $1.8 billion, indicating a robust strategy for capital allocation and a focus on enhancing shareholder value.
- Operating Cash Flow : The company reported an operating cash flow of $5.8 billion, which represents nearly 1.0 times its GAAP net income, showcasing strong liquidity and operational efficiency.
Comments from Company Officers
Gail K. Boudreaux, President and CEO of Elevance Health, emphasized the company's ongoing dedication to transforming healthcare delivery through innovative models and cost-effective solutions. Boudreaux noted the importance of sustainable growth and improving healthcare experiences, reaffirming the company's strategic focus for the future.
Dividends and Share Repurchases
Elevance Health has committed to returning value to its shareholders through an attractive dividend policy. The quarterly dividend for Q1 2025 was increased to $1.71 per share, reflecting a 5% hike. Furthermore, the company maintains a robust share repurchase program, with $9.3 billion in authorization remaining.
Elevance Health Stock Forecast
Based on the latest financial performance and strategic initiatives, Elevance Health is well-positioned for future growth. Current market conditions, including a market capitalization of $124.5 billion and a last trading price of $390.73, suggest a favorable outlook. The stock experienced a 0.39% boost following the earnings release, indicating positive market sentiment.
Stock Price Projection
- High Projection : $415 - Reflects potential realized growth from strategic initiatives, ongoing innovation, and improved market conditions.
- Low Projection : $370 - Considers potential macroeconomic challenges and competitive pressures within the healthcare industry.
In conclusion, Elevance Health continues to demonstrate strong financial and operational performance. With strategic initiatives and a focus on shareholder value, the company is well-equipped to navigate the challenges and opportunities ahead in the healthcare market.
For more in-depth analysis and insights, stay tuned with our platform to stay ahead of the market.
